Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the response rate and response duration with the
combination of low-dose rituximab, romiplostim and high-dose dexamethasone.